Optimer Pharmaceuticals, Inc. announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America in Philadelphia, PA. Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish Gene
Vince and Associates Clinical Research, a leading provider of Phase I-IV clinical research trials, announced that Dr. Bradley Vince, Medical Director and President, shared his expertise at the Exploratory Development World Congress on October 20, 2009 in Boston, Massachusetts.
Emerson Resources, Inc., a premier pharmaceutical solutions company, announced that it has formed a strategic partnership with Bio Research, a contract research organization that specializes in the agrichemical and related industries, to further extend its business development capabilities.
GE Healthcare, a unit of General Electric Company, announces the global launch of the first biomolecular imaging systems developed as part of its strategic alliance with FUJIFILM.
MedSource, a Contract Research Organization providing Phase I-IV clinical trials support, announced that Ms. Parisa Jabbarzadegan has joined its company as Associate Director of Clinical Operations.
POZEN Inc. announced today the start of enrollment for the phase 3 studies for PA32540. "We believe that PA32540 could address the needs of certain patients with cardiovascular disease," said John Fort, MD, Chief Medical Officer, POZEN. About the Studies. POZEN is conducting two pivotal phase 3 studies and one long-term safety study.
Quintiles announced that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca's clinical pharmacology studies across multiple therapy areas and around the globe. As a result of the alliance, Quintiles will assume the operational responsibilities for the majority of AstraZeneca's clinic
ChatAboutPennyStocks tracks stocks daily and is pleased to offer its hot stock alerts. Join Today to make sure you receive out Next Massive Stock Pick on Dec 01, 2009. Signup: http://www.chataboutpennystocks.com/component/user/?task=register.
Advanced Cell Technology, Inc. announced today that it filed an Investigational New Drug Application with the US Food and Drug Administration to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy.
19 November 2009 - Canadian clinical-stage biotechnology company Aegera Therapeutics Inc said today it has started dosing of the first patient in a randomised Phase IIb study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
Aldagen, a biopharmaceutical company, has reported positive results from a Phase I clinical trial of ALD-201, a cell therapy being developed as a treatment for ischemic heart failure. In the study, ALD-201 was found to be well-tolerated and to improve myocardial perfusion.
Alexza Pharmaceuticals, Inc. announced today that its corporate presentation will be webcast live during the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 9:00 a.m. Eastern Time.
Study to Assess Efficacy of Once-Weekly Inhaled Non-Steroidal Anti-Inflammatory in Suppressing Asthmatic Response. Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial.
11/19/09 AVI BioPharma, Inc., a developer of RNA-based drugs, today announced presentations on the company's exon skipping therapy for Duchenne muscular dystrophy at the TREAT-NMD / NIH International Conference taking place Nov. 17-19 in Brussels, Belgium. At the conference, data from the company's clinical and preclinical programs were presente
Dublin - Research and Markets has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering. Cancer therapies are geared towards controlling the growth of cancerous tumors, and preventing the spread of cancer to other organs of the body.
Catalent Pharma Solutions, the leading provider of advanced oral drug delivery technologies to the pharmaceutical industry, has entered into a strategic alliance with Endotis Pharma for the development of oral formulations of synthetic oligosaccharides.
11/19/09 Cytokinetics, Incorporated announced today that abstracts summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E, were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held November 15-19, 2009 in Boston, Massachusetts.
Operation in Russia further strengthens company's long lasting expertise in Eastern Europe. Ecron Acunova, a full-service clinical research organization, with offices across Europe, in India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow, Russia in October 2009.
Endocyte, Inc., a cancer drug discovery and development company, presented data from a Phase 2a clinical trial for EC145, currently in development as a potential treatment for advanced ovarian cancer. The study participants had disease that was highly resistant to standard chemotherapy.
Novel pipeline continues to advance and show promise. Enzon Pharmaceuticals, Inc. presented data from its pipeline programs at the 2009 EORTC-NCI-AACR annual meeting in Boston, Massachusetts. "We are pleased to present new data from our novel pipeline programs. The Posters and Abstracts that were presented included: PEG-SN38.
Epiphany Biosciences announces positive results from its phase 2b trial in shingles. The Epiphany Biosciences press release reads as follows; Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 in patients with shingles infection. Once-daily EPB-348 at two grams met its primary endpoint of non-inferiority to valac
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, issued the following Letter to Shareholders today: Dear ImmunoCellular Therapeutics Shareholder: As we approach year-end, I thought it would be an opportune time to provide you with an update on the Company.
Regulatory News: Medivir: The Epiphany Biosciences press release reads as follows; Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 in patients with shingles infection. Once-daily EPB-348 at two grams met its primary endpoint of non-inferiority to valacyclovir.
Merrion Pharmaceuticals plc, an international specialty pharmaceutical company, announced its interim results for the six-month period that ended June 30. Merrion's four internal product development programs are made possible by the GIPET technology, which enables the company to make tablet forms of drugs that otherwise have to be given by injec
